This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Health stocks looked vibrant Wednesday after a plethora of regulatory and clinical updates.

First, a Food and Drug Administration advisory panel on Tuesday voted against the setting targets that would have further restricted the use of Amgen's (AMGN) anemia drug Epogen and Johnson & Johnson's (JNJ) Procrit in dialysis and predialysis patients, instead opting for a range to guide the use of the drugs in those patients. Amgen shares were up $2.02, or 3.8%, to $55.94 Wednesday.

A smaller-cap company, Vision-Sciences (VSCI), took off Wednesday after announcing that it received 510(k) clearance from the FDA to market a new line of digital, video-based flexible endoscopes, which come with an integrated "built-in" light source so that a separate camera head, light cable and optical coupler aren't needed.

The ENT (ear, nose and throat) and TNE (transnasal esophagoscopy) scopes are the first two in a series to be introduced by Vision-Sciences. Shares rose 48 cents, or 26%, to $2.26.

And for the second time in two weeks, investors fueled Cardica (CRDC) shares. The company said Wednesday that it received European CE Mark approval for its C-Port Flex A Anastomosis System, which attaches blood vessels and grafts in less-invasive coronary artery bypass graft (CABG) procedures. Cardica added $1.28, or 14.9%, to $9.93.

In the clinical update arena, biopharmaceutical company Novavax (NVAX) said that several candidates have emerged from an ongoing discovery program to create a novel vaccine to prevent disease associated with the varicella zoster virus (VZV) in older adults, and that the candidates are now targeted for preclinical development. Shares climbed 31 cents, or 9.2%, to $3.72.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs